Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil for Fatigue in Malignant Glioma
NCT00766467Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2008
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer-related fatigue (CRF) comparing Armodafinil with Placebo (2 arms). Primary endpoint: Change From Baseline in Fatigue (FACIT-F) at 43 days. Started Sep 2008; status: completed.
02
Drugs
armodafinil
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT00766467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00766467.